Airway infantile hemangioma

Airway infantile hemangioma is a rare vascular tumor characterized by the proliferation of benign blood vessels (hemangiomas) within the subglottic region or other parts of the airway during infancy. Also referred to as subglottic hemangioma or infantile subglottic hemangioma, this condition primarily affects the respiratory system and can cause progressive, potentially life-threatening airway obstruction. The hemangioma typically follows the natural history of infantile hemangiomas, with a proliferative growth phase during the first weeks to months of life, followed by a slow involution phase over several years. However, because of its critical location in the airway, even a small lesion can produce significant symptoms. Key clinical features include biphasic stridor (both inspiratory and expiratory), a barking or croup-like cough, respiratory distress, and feeding difficulties. Symptoms often worsen during the proliferative phase and may initially be misdiagnosed as recurrent croup. Approximately 50% of affected infants also have cutaneous hemangiomas, particularly in a "beard distribution" involving the lower face, chin, and anterior neck, which can serve as an important diagnostic clue. Diagnosis is typically confirmed by direct laryngoscopy and bronchoscopy, which reveals a compressible, often asymmetric subglottic mass. The treatment landscape has been transformed by the introduction of oral propranolol (a beta-blocker), which is now considered first-line therapy and has dramatically reduced the need for surgical intervention. Propranolol therapy typically leads to rapid reduction in hemangioma size and improvement in airway symptoms. In cases that do not respond adequately to medical therapy, or in emergent situations, treatment options include systemic corticosteroids, laser therapy, surgical excision, or tracheostomy. Early diagnosis and prompt initiation of treatment are critical to prevent severe airway compromise.

Common questions about Airway infantile hemangioma